文献速递脊柱外科骨质疏松与代谢性骨病

维生素D与双膦酸盐治疗优化脊柱融合结局的系统综述与荟萃分析

Vitamin D and Bisphosphonate Therapy for Optimizing Outcomes in Spinal Fusion: A Systematic Review and Meta-Analysis.
PubMed 文献 · Spine (Phila Pa 1976) · 2026-02-23

本系统综述与荟萃分析评估了围手术期维生素D补充和双膦酸盐治疗对脊柱融合结局、患者报告功能障碍与疼痛、姿势稳定性及椎体骨折风险的影响。维生素D提高一年融合率并改善ODI和姿势稳定性,双膦酸盐加速早期融合、抑制骨转换并降低骨折风险。

要点

  • 维生素D补充提高一年融合率并改善功能与姿势稳定性。
  • 双膦酸盐加速早期融合、抑制P1NP并降低椎体骨折风险。
  • 围手术期骨健康优化需根据患者情况采取多模式个体化策略。

核心结论

  • 维生素D加速早期融合并适度改善长期功能,双膦酸盐提供骨折保护和骨转换抑制,支持围手术期多模式骨健康优化。

研究设计与样本

  • 遵循PRISMA的系统综述与荟萃分析,检索PubMed、Embase和Google Scholar至2025年1月,纳入随机对照和前瞻性比较试验,比较维生素D与安慰剂/无补充及双膦酸盐与维生素D。

主要发现

  • 维生素D与安慰剂相比,一年融合率RR约1.25,六个月和一年ODI改善MD约6.90和8.56,早期VAS获益MD 1.14,OSI改善SMD 0.93。
  • 双膦酸盐与维生素D相比,加速早期融合但一年时结局相似,一年ODI favoring维生素D,VAS无差异,双膦酸盐抑制P1NP并降低骨折风险RR 0.10。

关键数值与推荐

  • 维生素D vs 安慰剂:一年融合率RR约1.25;六个月ODI MD约6.90,一年ODI MD约8.56;VAS MD 1.14;OSI SMD 0.93。
  • 双膦酸盐 vs 维生素D:骨折风险RR 0.10;P1NP受抑制;一年ODI favoring维生素D;VAS无差异。

临床怎么用

  • 围手术期可考虑补充维生素D以促进早期融合和改善功能,双膦酸盐用于骨折高风险患者以抑制骨转换和降低椎体骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Systematic review and meta-analysis. OBJECTIVE: To systematically evaluate the impact of perioperative vitamin D supplementation and bisphosphonate therapy on spinal fusion outcomes, patient-reported disability and pain, postural stability, and vertebral fracture risk. BACKGROUND: Bone health optimization is critical for successful spinal fusion. While vitamin D and bisphosphonate supplementation have been studied individually, their comparative and combined effects remain unclear. METHODS: A PRISMA-compliant systematic review and meta-analysis were performed (PubMed, Embase, and Google Scholar; through January 2025). Eligible randomized controlled and prospective comparative trials evaluated: (1) vitamin D versus placebo/no supplement and (2) bisphosphonates versus vitamin D. Primary outcomes were fusion rates and vertebral compression fractures (VCFs). Secondary outcomes included functional scores (ODI), VAS, postural stability, bone turnover markers (P1NP), and BMD. Risk ratios (RR) and mean differences (MD/SMD) with 95% CI were pooled. RESULTS: For the vitamin D versus placebo analysis, increased fusion at one year (RR: ∼1.25), improved ODI at six months and one year (MD: ∼6.90, 8.56), and provided a small early VAS benefit (MD: 1.14). OSI improved significantly (SMD: 0.93). For Bisphosphonates versus vitamin D analysis, bisphosphonate therapy accelerated early fusion, but by one year, outcomes were similar. ODI favored vitamin D at one year, while VAS showed no difference. Bisphosphonates suppressed P1NP and reduced fracture risk (RR: 0.10). CONCLUSIONS: Vitamin D accelerates early fusion and modestly improves long-term function and bisphosphonates provide fracture protection and turnover suppression. These findings support a tailored, multimodal approach to perioperative bone health optimization in spinal fusion. LEVEL OF EVIDENCE: Level II.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Sadh P, Kim J, Furlong C, et al. Vitamin D and Bisphosphonate Therapy for Optimizing Outcomes in Spinal Fusion: A Systematic Review and Meta-Analysis. Spine (Phila Pa 1976). 2026. PMID: 41740615. doi:10.1097/BRS.0000000000005655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。